ERAS
Price
$3.43
Change
+$0.04 (+1.18%)
Updated
Dec 24 closing price
Capitalization
973.13M
84 days until earnings call
Intraday BUY SELL Signals
KALV
Price
$15.79
Change
+$0.04 (+0.25%)
Updated
Dec 24 closing price
Capitalization
798.13M
Intraday BUY SELL Signals
Interact to see
Advertisement

ERAS vs KALV

Header iconERAS vs KALV Comparison
Open Charts ERAS vs KALVBanner chart's image
Erasca
Price$3.43
Change+$0.04 (+1.18%)
Volume$1.23M
Capitalization973.13M
KalVista Pharmaceuticals
Price$15.79
Change+$0.04 (+0.25%)
Volume$307.31K
Capitalization798.13M
ERAS vs KALV Comparison Chart in %
ERAS
Daily Signal:
Gain/Loss:
KALV
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
ERAS vs. KALV commentary
Dec 26, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ERAS is a Hold and KALV is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Dec 26, 2025
Stock price -- (ERAS: $3.43 vs. KALV: $15.79)
Brand notoriety: ERAS and KALV are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ERAS: 63% vs. KALV: 23%
Market capitalization -- ERAS: $973.13M vs. KALV: $798.13M
ERAS [@Biotechnology] is valued at $973.13M. KALV’s [@Biotechnology] market capitalization is $798.13M. The market cap for tickers in the [@Biotechnology] industry ranges from $117.47B to $0. The average market capitalization across the [@Biotechnology] industry is $2.23B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ERAS’s FA Score shows that 1 FA rating(s) are green whileKALV’s FA Score has 0 green FA rating(s).

  • ERAS’s FA Score: 1 green, 4 red.
  • KALV’s FA Score: 0 green, 5 red.
According to our system of comparison, ERAS is a better buy in the long-term than KALV.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ERAS’s TA Score shows that 2 TA indicator(s) are bullish while KALV’s TA Score has 5 bullish TA indicator(s).

  • ERAS’s TA Score: 2 bullish, 5 bearish.
  • KALV’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, KALV is a better buy in the short-term than ERAS.

Price Growth

ERAS (@Biotechnology) experienced а -5.77% price change this week, while KALV (@Biotechnology) price change was +6.33% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.88%. For the same industry, the average monthly price growth was +4.46%, and the average quarterly price growth was +55.39%.

Reported Earning Dates

ERAS is expected to report earnings on Mar 19, 2026.

Industries' Descriptions

@Biotechnology (+2.88% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ERAS($973M) has a higher market cap than KALV($798M). KALV YTD gains are higher at: 86.423 vs. ERAS (36.653). ERAS has higher annual earnings (EBITDA): -131.32M vs. KALV (-187.27M). KALV has more cash in the bank: 309M vs. ERAS (288M). ERAS has less debt than KALV: ERAS (48.3M) vs KALV (150M). KALV has higher revenues than ERAS: KALV (1.43M) vs ERAS (0).
ERASKALVERAS / KALV
Capitalization973M798M122%
EBITDA-131.32M-187.27M70%
Gain YTD36.65386.42342%
P/E RatioN/AN/A-
Revenue01.43M-
Total Cash288M309M93%
Total Debt48.3M150M32%
FUNDAMENTALS RATINGS
KALV: Fundamental Ratings
KALV
OUTLOOK RATING
1..100
27
VALUATION
overvalued / fair valued / undervalued
1..100
82
Overvalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
100
PRICE GROWTH RATING
1..100
39
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
ERASKALV
RSI
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
82%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
89%
Bullish Trend 2 days ago
84%
Momentum
ODDS (%)
N/A
Bearish Trend 2 days ago
84%
MACD
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
87%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
89%
Bullish Trend 2 days ago
80%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
81%
Advances
ODDS (%)
Bullish Trend 9 days ago
81%
Bullish Trend 4 days ago
78%
Declines
ODDS (%)
Bearish Trend 7 days ago
88%
Bearish Trend 9 days ago
86%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 2 days ago
83%
Aroon
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 2 days ago
78%
View a ticker or compare two or three
Interact to see
Advertisement
ERAS
Daily Signal:
Gain/Loss:
KALV
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
REINX15.800.11
+0.70%
Invesco Real Estate Investor
ITRAX25.110.05
+0.20%
VY® T. Rowe Price Capital Apprec A
AIERX20.350.01
+0.05%
Invesco EQV International Equity R
FSYCX11.55N/A
N/A
Fidelity Advisor Sustainable Intl Eq C
ARTHX22.44-0.02
-0.09%
Artisan Global Equity Investor

ERAS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ERAS has been loosely correlated with RVMD. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if ERAS jumps, then RVMD could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ERAS
1D Price
Change %
ERAS100%
+1.18%
RVMD - ERAS
51%
Loosely correlated
+1.15%
EYPT - ERAS
50%
Loosely correlated
-0.65%
XNCR - ERAS
50%
Loosely correlated
-0.13%
OCUL - ERAS
49%
Loosely correlated
-0.24%
CLDX - ERAS
46%
Loosely correlated
+0.94%
More

KALV and

Correlation & Price change

A.I.dvisor indicates that over the last year, KALV has been loosely correlated with ABEO. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if KALV jumps, then ABEO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To KALV
1D Price
Change %
KALV100%
+0.25%
ABEO - KALV
43%
Loosely correlated
+2.08%
SYRE - KALV
41%
Loosely correlated
-0.54%
VRDN - KALV
41%
Loosely correlated
+0.53%
AVBP - KALV
40%
Loosely correlated
-0.13%
ERAS - KALV
40%
Loosely correlated
+1.18%
More